fotemustine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
antineoplastic, alkylating agents, (beta-chloroethyl)amine derivatives 1249 92118-27-9

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • fotemustine
  • muphoran
  • mustophorane
  • Molecular weight: 315.69
  • Formula: C9H19ClN3O5P
  • CLOGP: 1.39
  • LIPINSKI: 0
  • HAC: 8
  • HDO: 1
  • TPSA: 97.30
  • ALOGS: -1.89
  • ROTB: 9

Drug dosage:

None

ADMET properties:

PropertyValueReference
Vd (Volume of distribution) 0.62 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 18.50 mL/min/kg Lombardo F, Berellini G, Obach RS
t_half (Half-life) 0.38 hours Lombardo F, Berellini G, Obach RS

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
kinase-safety-class ACVR2A,ACVR2B,ACVRL1,AKT2,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK2,CDK4,CDK5,CDK9,DDR1,DYRK1B,EGFR,EIF2AK3,EPHB4,ERBB2,GRK2,GSK3B,IGF1R,ITK,JAK2,JAK3,MAP2K6,MAP3K21,MAP3K7,MAPK10,MAPK7,MAPK9,MAPKAPK2,MET,MTOR,NTRK2,PDK1,PDK2,PDK4,PDPK1,PIK3CA,PIK3CB,PIK3CD,PIK3CG,PIM2,PLK1,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,TTK,ZAP70 56
kinase-selectivity-class AXL,BRAF,CDK9,EPHB4,ERBB2,GRK2,MAP2K6,MAPK7,STK33,SYK,TEK,ZAP70 12
pfas-class PFAS structural alert (1 = True, 0 = False) 0

Approvals:

None

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Diffuse large B-cell lymphoma recurrent 65.63 47.87 14 408 4872 42616041

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Acute myeloid leukaemia 76.44 57.51 22 725 38088 110550464
Diffuse large B-cell lymphoma recurrent 61.54 57.51 13 734 6286 110582266
Tonsillar haemorrhage 58.35 57.51 8 739 290 110588262

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC L01AD05 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
ALKYLATING AGENTS
Nitrosoureas
MeSH PA D000970 Antineoplastic Agents
CHEBI has role CHEBI:22333 alkylating agent
CHEBI has role CHEBI:35610 antineoplastic agent

Related Drugs by ATC class:

L01AD Nitrosoureas 7 drugs
carmustinelomustinenimustineranimustinesemustinestreptozocinuracil mustard

Drug Use | Suggest Off label Use Form| |View source of the data|

None




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
D07255 KEGG_DRUG
C0060696 UMLSCUI
CHEBI:131848 CHEBI
CHEMBL549386 ChEMBL_ID
DB04106 DRUGBANK_ID
C054368 MESH_SUPPLEMENTAL_RECORD_UI
104799 PUBCHEM_CID
5982 INN_ID
GQ7JL9P5I2 UNII
005271 NDDF
697996006 SNOMEDCT_US

Pharmaceutical products:

None